HK-660S not checked

CuromeBiosciences

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
1 active
2 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
Tested for
Primary Sclerosing Cholangitis (PSC)
Main trialPhase 2
“The cause of PSC is unknown.To date, there is no treatment besides liver transplantation proven to improve PSC prognosis. However, there is a clear medical unmet need yet for patients with PSC, due to risks and complications of liver transplantation. This is a two-part, Phase 2b, randomized, double-blind, placebo-controlled study designed to assess the efficacy and safety of HK-660S in patients with PSC. The primary objective is to evaluate the effects of HK-660S on serum ALP improvement (reduction of 20% or more) over 12 weeks of treatment in patients with PSC.”In the company’s words, NCT06975150 on ClinicalTrials.gov

Other drugs for Primary Sclerosing Cholangitis (PSC)

All 7 drugs for Primary Sclerosing Cholangitis (PSC)

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 2Not yet recruiting 30 Aug 2028 Efficacy and Safety of HK-660S in the Treatment of Primary Sclerosing Cholangitis
Phase 2Completed 23 Jun 2023 Evaluation of the Safety and Efficacy of HK-660S in Patients With Primary Sclerosing Cholangitis
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow HK-660S

Following is part of Solo: you see every change to HK-660S the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in